- Home
- EVN vs VOR Comparison
EVN vs VOR Comparison
Compare EVN & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EVN | VOR |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 429.2M | 345.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | EVN | VOR |
|---|---|---|
| Price | $11.03 | $12.98 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $64.78 |
| AVG Volume (30 Days) | 101.2K | ★ 866.3K |
| Earning Date | 01-01-0001 | 03-19-2026 |
| Dividend Yield | ★ 4.78% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.64 | $2.62 |
| 52 Week High | $10.45 | $65.80 |
Technical Indicators
Market Signals| Indicator | EVN | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 61.14 | 47.12 |
| Support Level | $10.95 | $12.60 |
| Resistance Level | $11.10 | $14.73 |
| Average True Range (ATR) | 0.10 | 1.17 |
| MACD | 0.03 | -0.12 |
| Stochastic Oscillator | 89.13 | 46.05 |
Price Performance
Historical ComparisonAbout EVN Eaton Vance Municipal Income Trust
Eaton Vance Municipal Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax. The trust's portfolio of investments majorly consists of debt instruments of governments, municipal organizations the interest on which is exempt from regular federal income tax and has also some exposure to corporate bonds and other instruments.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.